These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 37302581)

  • 1. For long-term outcomes, is the impact of cirrhosis more important than HBsAg seroclearance?
    Liu X; Wen X; Lu F
    J Hepatol; 2024 Jan; 80(1):e31-e32. PubMed ID: 37302581
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to: "For long-term outcomes, is the impact of cirrhosis more important than HBsAg seroclearance?".
    Lai JC; Wong GL; Yip TC
    J Hepatol; 2024 Jan; 80(1):e32-e34. PubMed ID: 37821018
    [No Abstract]   [Full Text] [Related]  

  • 3. Risk of hepatic decompensation but not hepatocellular carcinoma decreases over time in patients with hepatitis B surface antigen loss.
    Yip TC; Wong VW; Lai MS; Lai JC; Hui VW; Liang LY; Tse YK; Chan HL; Wong GL
    J Hepatol; 2023 Mar; 78(3):524-533. PubMed ID: 36463985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability.
    Kim GA; Lim YS; An J; Lee D; Shim JH; Kim KM; Lee HC; Chung YH; Lee YS; Suh DJ
    Gut; 2014 Aug; 63(8):1325-32. PubMed ID: 24162593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B.
    Arase Y; Ikeda K; Suzuki F; Suzuki Y; Saitoh S; Kobayashi M; Akuta N; Someya T; Hosaka T; Sezaki H; Kobayashi M; Kumada H
    Am J Med; 2006 Jan; 119(1):71.e9-16. PubMed ID: 16431195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
    Yang H; Bae SH; Nam H; Lee HL; Lee SW; Yoo SH; Song MJ; Kwon JH; Nam SW; Choi JY; Yoon SK; Jang JW
    J Hepatol; 2022 Sep; 77(3):632-641. PubMed ID: 35398462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma.
    Yuen MF; Wong DK; Fung J; Ip P; But D; Hung I; Lau K; Yuen JC; Lai CL
    Gastroenterology; 2008 Oct; 135(4):1192-9. PubMed ID: 18722377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of HBsAg seroclearance on late recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection.
    Yoo S; Kim JY; Lim YS; Han S; Choi J
    J Hepatol; 2022 Oct; 77(4):939-946. PubMed ID: 35643206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical features of HBsAg seroclearance in hepatitis B virus carriers in South Korea: A retrospective longitudinal study.
    Park YM; Lee SG
    World J Gastroenterol; 2016 Nov; 22(44):9836-9843. PubMed ID: 27956808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects.
    Yuen MF; Wong DK; Sablon E; Tse E; Ng IO; Yuan HJ; Siu CW; Sander TJ; Bourne EJ; Hall JG; Condreay LD; Lai CL
    Hepatology; 2004 Jun; 39(6):1694-701. PubMed ID: 15185311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcomes and predictive scores for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after hepatitis B e-antigen seroclearance.
    Fung J; Cheung KS; Wong DK; Mak LY; To WP; Seto WK; Lai CL; Yuen MF
    Hepatology; 2018 Aug; 68(2):462-472. PubMed ID: 29534307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues.
    Yip TC; Wong GL; Chan HL; Tse YK; Lam KL; Lui GC; Wong VW
    J Hepatol; 2019 Mar; 70(3):361-370. PubMed ID: 30367899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association Between Seroclearance of Hepatitis B Surface Antigen and Long-term Clinical Outcomes of Patients With Chronic Hepatitis B Virus Infection: Systematic Review and Meta-analysis.
    Anderson RT; Choi HSJ; Lenz O; Peters MG; Janssen HLA; Mishra P; Donaldson E; Westman G; Buchholz S; Miller V; Hansen BE
    Clin Gastroenterol Hepatol; 2021 Mar; 19(3):463-472. PubMed ID: 32473348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced Liver Fibrosis Score Stratifies Hepatocellular Carcinoma Risk in Patients With Hepatitis B Surface Antigen Seroclearance.
    Mak LY; Cheung KS; Hui RW; Wong DK; Fung J; Yuen MF; Seto WK
    Clin Infect Dis; 2022 Dec; 75(12):2257-2259. PubMed ID: 35594565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Durability of hepatitis B surface antigen seroclearance and subsequent risk for hepatocellular carcinoma: A meta-analysis.
    Song A; Wang X; Lu J; Jin Y; Ma L; Hu Z; Zheng Y; Shen C; Chen X
    J Viral Hepat; 2021 Apr; 28(4):601-612. PubMed ID: 33455067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk and Risk Score Performance of Hepatocellular Carcinoma Development in Patients With Hepatitis B Surface Antigen Seroclearance.
    Park Y; Lee JH; Sinn DH; Park JY; Kim MA; Kim YJ; Yoon JH; Kim DY; Ahn SH; Kang W; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
    Clin Transl Gastroenterol; 2021 Jan; 12(1):e00290. PubMed ID: 33433118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma.
    Liu J; Yang HI; Lee MH; Lu SN; Jen CL; Batrla-Utermann R; Wang LY; You SL; Hsiao CK; Chen PJ; Chen CJ;
    Gut; 2014 Oct; 63(10):1648-57. PubMed ID: 24225939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Long-Term Clinical Outcomes Between Spontaneous and Therapy-Induced HBsAg Seroclearance.
    Choi J; Yoo S; Lim YS
    Hepatology; 2021 Jun; 73(6):2155-2166. PubMed ID: 33131063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients: a need for surveillance.
    Kim GA; Lee HC; Kim MJ; Ha Y; Park EJ; An J; Lee D; Shim JH; Kim KM; Lim YS
    J Hepatol; 2015 May; 62(5):1092-9. PubMed ID: 25445399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcome of entecavir treatment of nucleos(t)ide analogue-naïve chronic hepatitis B patients in Japan.
    Suzuki F; Hosaka T; Suzuki Y; Sezaki H; Akuta N; Fujiyama S; Kawamura Y; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Mineta R; Suzuki Y; Kumada H
    J Gastroenterol; 2019 Feb; 54(2):182-193. PubMed ID: 30136216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.